COMPREHENSIVE EVALUATION OF IMMUNE FUNCTION IN PATIENTS RECEIVING MULTIMODAL THERAPY FOR HIGH-RISK NEUROBLASTOMA

$541,681FY2022Department of the ArmyDOD

Dana-Farber Cancer Institute, Inc.

Investigators